CN104688697A - 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 - Google Patents
用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 Download PDFInfo
- Publication number
- CN104688697A CN104688697A CN201510055041.5A CN201510055041A CN104688697A CN 104688697 A CN104688697 A CN 104688697A CN 201510055041 A CN201510055041 A CN 201510055041A CN 104688697 A CN104688697 A CN 104688697A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- activating agent
- pharmaceutically acceptable
- agent
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65882705P | 2005-03-07 | 2005-03-07 | |
US60/658827 | 2005-03-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680007187.1A Division CN101132779B (zh) | 2005-03-07 | 2006-02-22 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104688697A true CN104688697A (zh) | 2015-06-10 |
Family
ID=36507604
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680007187.1A Ceased CN101132779B (zh) | 2005-03-07 | 2006-02-22 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
CN201510055041.5A Pending CN104688697A (zh) | 2005-03-07 | 2006-02-22 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680007187.1A Ceased CN101132779B (zh) | 2005-03-07 | 2006-02-22 | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 |
Country Status (38)
Country | Link |
---|---|
US (2) | US9737488B2 (de) |
EP (1) | EP1868579B1 (de) |
JP (1) | JP5304241B2 (de) |
KR (1) | KR101335932B1 (de) |
CN (2) | CN101132779B (de) |
AR (1) | AR054234A1 (de) |
AT (1) | ATE482693T1 (de) |
AU (1) | AU2006222365B2 (de) |
BR (1) | BRPI0608840B8 (de) |
CA (1) | CA2601955C (de) |
CR (1) | CR9348A (de) |
CU (1) | CU23821A3 (de) |
CY (1) | CY1111065T1 (de) |
DE (1) | DE602006017188D1 (de) |
DK (1) | DK1868579T3 (de) |
DO (1) | DOP2006000057A (de) |
ES (1) | ES2351612T3 (de) |
GT (1) | GT200600096A (de) |
HK (2) | HK1118019A1 (de) |
HN (1) | HN2006009702A (de) |
HR (1) | HRP20100674T1 (de) |
IL (1) | IL185517A (de) |
MA (1) | MA29378B1 (de) |
MX (1) | MX2007010856A (de) |
MY (1) | MY162319A (de) |
NO (1) | NO343834B1 (de) |
NZ (1) | NZ561178A (de) |
PE (1) | PE20061345A1 (de) |
PL (1) | PL1868579T3 (de) |
PT (1) | PT1868579E (de) |
SG (1) | SG160364A1 (de) |
SI (1) | SI1868579T1 (de) |
TN (1) | TNSN07341A1 (de) |
TW (1) | TWI324928B (de) |
UA (1) | UA93673C2 (de) |
UY (1) | UY29410A1 (de) |
WO (1) | WO2006094626A1 (de) |
ZA (1) | ZA200707638B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
CA2526617C (en) | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
AU2004259760B9 (en) | 2003-07-23 | 2011-02-03 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
ES2387812T3 (es) | 2004-09-29 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | Forma termodinámicamente estable del tosilato BAY 43-9006 |
MX2007010856A (es) | 2005-03-07 | 2007-11-12 | Bayer Healthcare Ag | Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer. |
JP2009513707A (ja) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ジアリールウレア及び併用剤 |
US20080213374A1 (en) * | 2006-07-10 | 2008-09-04 | Elan Pharma International Limited | Nanoparticulate sorafenib formulations |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008089389A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
CN105535008A (zh) | 2008-05-15 | 2016-05-04 | 细胞基因公司 | 胞苷类似物的口服制剂和其使用方法 |
EP2440531A2 (de) * | 2009-06-12 | 2012-04-18 | Ratiopharm GmbH | 4-[4-[[4-chlor-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridin-2-carboxamid-polymorphe |
CA2788146C (en) | 2010-01-29 | 2014-11-25 | Ranbaxy Laboratories Limited | Sorafenib dimethtyl sulphoxide solvate |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2013538840A (ja) | 2010-10-01 | 2013-10-17 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換n−(2−アリールアミノ)アリールスルホンアミドを含有する組み合わせ |
EP2559431A1 (de) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid |
WO2013110644A1 (en) | 2012-01-23 | 2013-08-01 | Sandoz Ag | Pharmaceutical composition containing crystalline sorafenib tosylate |
MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
RU2017106795A (ru) | 2014-08-07 | 2018-09-07 | Фармасайкликс Элэлси | Новые составы ингибитора тирозинкиназы брутона |
ES2971597T3 (es) | 2015-03-03 | 2024-06-06 | Pharmacyclics Llc | Formulaciones farmacéuticas del inhibidor de la tirosina quinasa de Bruton |
CN107532379B (zh) * | 2015-05-14 | 2020-12-22 | 杜邦营养美国有限公司 | 制造漂白的微晶纤维素的方法 |
CA3016809C (en) * | 2016-03-14 | 2024-03-12 | Santen Pharmaceutical Co., Ltd. | Antiseptic agent comprising meglumine or salt thereof |
CN106344530B (zh) * | 2016-09-30 | 2019-03-19 | 京津冀联创药物研究(北京)有限公司 | 一种索拉非尼组合物及其制备方法 |
CA3064829C (en) | 2017-05-26 | 2023-08-22 | Bruin Biosciences, Inc. | Chemoembolization agents |
US11179322B2 (en) | 2018-07-10 | 2021-11-23 | Novocure Gmbh | Methods and compositions for treating tumors with TTFields and sorafenib |
WO2018211336A2 (en) * | 2018-09-07 | 2018-11-22 | Alvogen Malta Operations (Row) Ltd | Solid dosage form containing sorafenib tosylate |
CA3118324A1 (en) | 2018-11-01 | 2020-05-07 | Syros Pharmaceuticals, Inc. | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) |
AU2020326612A1 (en) | 2019-08-02 | 2022-03-17 | Onehealthcompany, Inc. | Treatment of canine cancers |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125359A1 (en) * | 2001-12-04 | 2003-07-03 | Lyons John F. | RAF-MEK-ERK pathway inhibitors to treat cancer |
US20050038080A1 (en) * | 2003-07-23 | 2005-02-17 | Stephen Boyer | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3125359A (en) * | 1964-03-17 | Push-pull breakaway coupling | ||
NL282262A (de) * | 1961-11-08 | |||
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
DK607188A (da) | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US6106865A (en) * | 1995-01-09 | 2000-08-22 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
GB9501127D0 (en) | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
WO1997004765A1 (en) | 1995-07-25 | 1997-02-13 | Smithkline Beecham Corporation | INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS |
WO1997040028A1 (en) | 1996-04-23 | 1997-10-30 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
DE1019040T1 (de) | 1997-05-23 | 2001-02-08 | Bayer Corp., West Haven | Hemmung von p38 kinase aktivität durch arylharnstoff |
ATE399007T1 (de) | 1997-05-23 | 2008-07-15 | Bayer Pharmaceuticals Corp | Raf kinase hemmer |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
AU1939999A (en) | 1997-12-22 | 1999-07-12 | Bayer Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
JP4403482B2 (ja) | 1997-12-22 | 2010-01-27 | バイエル コーポレイション | 置換複素環尿素合成のための中間体およびその製造方法 |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
BR9814361A (pt) | 1997-12-22 | 2001-11-27 | Bayer Ag | Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila |
AU762077B2 (en) | 1997-12-22 | 2003-06-19 | Bayer Healthcare Llc | Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas |
RU2232015C2 (ru) | 1997-12-22 | 2004-07-10 | Байер Копэрейшн | Способ подавления роста опухолевых клеток, опосредованного киназой raf, гетероциклические производные мочевины (варианты), фармацевтическая композиция (варианты) |
DE1049664T1 (de) | 1997-12-22 | 2001-05-03 | Bayer Corp., Pittsburgh | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
US20010014352A1 (en) | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20030087849A1 (en) | 2001-07-03 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of HKR1 expression |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
WO2000043366A1 (fr) * | 1999-01-22 | 2000-07-27 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline |
EP1309315B1 (de) * | 2000-08-18 | 2006-06-14 | Pharmacia Corporation | Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AR035792A1 (es) | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo |
DE60218445T2 (de) | 2001-04-20 | 2007-11-29 | Bayer Pharmaceuticals Corp., West Haven | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20030207914A1 (en) * | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
WO2003047579A1 (en) | 2001-12-03 | 2003-06-12 | Bayer Pharmaceuticals Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
PT1478358E (pt) * | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
ES2378670T3 (es) * | 2002-02-11 | 2012-04-16 | Bayer Healthcare, Llc | Aril ureas como inhibidores de cinasas |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
WO2003101444A1 (en) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
MXPA05009104A (es) | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos. |
MXPA05009103A (es) | 2003-02-28 | 2006-04-18 | Bayer Pharmaceuticals Corp | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. |
MXPA05009102A (es) | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos. |
US6896863B2 (en) * | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
CA2526617C (en) * | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
WO2005009367A2 (en) | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
CA2537991A1 (en) * | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
US7552093B2 (en) * | 2003-12-04 | 2009-06-23 | Black Duck Software, Inc. | Resolving license dependencies for aggregations of legally-protectable content |
CA2548394A1 (en) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
EP1751139B1 (de) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
MXPA06015267A (es) | 2004-06-22 | 2007-03-15 | Pfizer Prod Inc | Antagonistas diazabiciclicos del receptor histamina-3. |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
MX2007002398A (es) | 2004-08-27 | 2007-05-15 | Bayer Pharmaceuticals Corp | Nuevas composiciones farmaceuticas para el tratamiento de cancer. |
ES2387812T3 (es) | 2004-09-29 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | Forma termodinámicamente estable del tosilato BAY 43-9006 |
SI1797037T1 (sl) | 2004-09-29 | 2015-06-30 | Bayer Healthcare Llc | Postopek priprave 4-(4-((((4-kloro-3-(trifluorometil)fenil)amino)karbonil)amino) fenioksi)N-metilpiridin-2-karboksamida |
MX2007010856A (es) | 2005-03-07 | 2007-11-12 | Bayer Healthcare Ag | Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer. |
CN101257903A (zh) | 2005-05-27 | 2008-09-03 | 拜耳医药保健股份公司 | 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗 |
AU2006251428A1 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
EP1937837A2 (de) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Verfahren und kits zur vorhersage von therapieerfolg, nichtwiederauftreten und gesamtüberleben bei krebstherapien |
US20090221010A1 (en) * | 2005-10-21 | 2009-09-03 | Elting James J | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy |
JP2009513707A (ja) * | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ジアリールウレア及び併用剤 |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
EP1954272A2 (de) | 2005-10-31 | 2008-08-13 | Bayer Pharmaceuticals Corporation | Krebsbehandlung mit sorafenib |
RU2008121751A (ru) * | 2005-11-02 | 2009-12-20 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний |
RU2008121754A (ru) | 2005-11-02 | 2009-12-20 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний |
ATE493986T1 (de) | 2005-11-10 | 2011-01-15 | Bayer Schering Pharma Ag | Diarylharnstoffe zur behandlung von pulmonaler hypertonie |
EP1963849A2 (de) | 2005-11-14 | 2008-09-03 | Bayer Healthcare, LLC | Verfahren zur vorhersage und prognose von krebs und überwachung der krebstherapie |
JP2009515978A (ja) | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
WO2007059155A1 (en) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
JP2009518298A (ja) | 2005-12-01 | 2009-05-07 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療に有用な尿素化合物 |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
US8101773B2 (en) | 2006-12-20 | 2012-01-24 | Bayer Healthcare Llc | Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer |
WO2008089389A2 (en) | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
EP2559431A1 (de) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid |
-
2006
- 2006-02-22 MX MX2007010856A patent/MX2007010856A/es active IP Right Grant
- 2006-02-22 AU AU2006222365A patent/AU2006222365B2/en active Active
- 2006-02-22 DE DE602006017188T patent/DE602006017188D1/de active Active
- 2006-02-22 JP JP2008500066A patent/JP5304241B2/ja active Active
- 2006-02-22 PL PL06707141T patent/PL1868579T3/pl unknown
- 2006-02-22 PT PT06707141T patent/PT1868579E/pt unknown
- 2006-02-22 AT AT06707141T patent/ATE482693T1/de active
- 2006-02-22 DK DK06707141.5T patent/DK1868579T3/da active
- 2006-02-22 BR BRPI0608840A patent/BRPI0608840B8/pt active IP Right Grant
- 2006-02-22 EP EP06707141A patent/EP1868579B1/de not_active Revoked
- 2006-02-22 SI SI200630863T patent/SI1868579T1/sl unknown
- 2006-02-22 CN CN200680007187.1A patent/CN101132779B/zh not_active Ceased
- 2006-02-22 CN CN201510055041.5A patent/CN104688697A/zh active Pending
- 2006-02-22 ES ES06707141T patent/ES2351612T3/es active Active
- 2006-02-22 NZ NZ561178A patent/NZ561178A/en unknown
- 2006-02-22 WO PCT/EP2006/001574 patent/WO2006094626A1/en active Application Filing
- 2006-02-22 US US11/885,930 patent/US9737488B2/en active Active
- 2006-02-22 KR KR1020077020370A patent/KR101335932B1/ko active IP Right Review Request
- 2006-02-22 CA CA2601955A patent/CA2601955C/en active Active
- 2006-02-22 UA UAA200711110A patent/UA93673C2/ru unknown
- 2006-02-22 SG SG201001549-3A patent/SG160364A1/en unknown
- 2006-02-27 GT GT200600096A patent/GT200600096A/es unknown
- 2006-03-03 MY MYPI20060919A patent/MY162319A/en unknown
- 2006-03-03 AR AR20060100820A patent/AR054234A1/es not_active Application Discontinuation
- 2006-03-03 DO DO2006000057A patent/DOP2006000057A/es unknown
- 2006-03-06 TW TW095107345A patent/TWI324928B/zh active
- 2006-03-06 PE PE2006000250A patent/PE20061345A1/es active IP Right Grant
- 2006-03-06 UY UY29410A patent/UY29410A1/es not_active Application Discontinuation
- 2006-03-07 HN HN2006009702A patent/HN2006009702A/es unknown
-
2007
- 2007-08-27 IL IL185517A patent/IL185517A/en active IP Right Grant
- 2007-08-28 CR CR9348A patent/CR9348A/es unknown
- 2007-08-30 CU CU20070203A patent/CU23821A3/es active IP Right Grant
- 2007-09-05 ZA ZA200707638A patent/ZA200707638B/xx unknown
- 2007-09-06 TN TNP2007000341A patent/TNSN07341A1/en unknown
- 2007-10-02 MA MA30267A patent/MA29378B1/fr unknown
- 2007-10-05 NO NO20075042A patent/NO343834B1/no unknown
-
2008
- 2008-08-19 HK HK08109248.3A patent/HK1118019A1/zh unknown
-
2010
- 2010-12-06 HR HR20100674T patent/HRP20100674T1/hr unknown
- 2010-12-10 CY CY20101101138T patent/CY1111065T1/el unknown
-
2015
- 2015-10-22 HK HK15110355.1A patent/HK1209620A1/xx unknown
-
2017
- 2017-08-22 US US15/683,210 patent/US20180036249A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030125359A1 (en) * | 2001-12-04 | 2003-07-03 | Lyons John F. | RAF-MEK-ERK pathway inhibitors to treat cancer |
US20050038080A1 (en) * | 2003-07-23 | 2005-02-17 | Stephen Boyer | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Non-Patent Citations (4)
Title |
---|
STRUMBERG等: "Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors", 《JOURNAL OF CLINICAL ONCOLOGY》 * |
刘雅敏 等主编: "《药物制剂常用辅料》", 31 January 1994, 天津科技翻译出版公司出版 * |
周建平: "《药剂学》", 31 March 2004, 化工工业出版社 * |
崔福德,等: "粉体学在制药工业中的应用", 《中国药剂学杂志》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101132779B (zh) | 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物 | |
EP1796642B1 (de) | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs | |
KR102451106B1 (ko) | 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물 | |
CN102548542A (zh) | 含有两种以上粒子的口腔速崩片 | |
MXPA06006677A (es) | Formas de dosis de torasemida de liberacion sostenida. | |
JP2023052494A (ja) | 抗凝固薬の即時放出医薬製剤及びその調製方法 | |
JP2013136537A (ja) | 錠剤及びその製造方法 | |
RU2420283C9 (ru) | Фармацевтическая композиция, содержащая омегакарбоксиарилзамещенную дифенилмочевину, для лечения рака | |
CN105267232A (zh) | 一种用于治疗丙型肝炎的药物制剂及其制备方法 | |
KR20040091135A (ko) | 염산 필지카이니드 함유 정제(건식) | |
RU2182483C1 (ru) | Комбинированное противотуберкулезное средство и способ его получения | |
EP0974343B1 (de) | Verfahren zur Herstellung einer festen Zubereitung enthaltend Metoprolol | |
EP4422603A1 (de) | Valbenazinzusammensetzungen | |
US20070184116A1 (en) | Pharmaceutical formulation containing unmilled flutamide | |
KR20050002856A (ko) | 염산 필지카이니드 함유 정제(습식) | |
EA046114B1 (ru) | Ингибитор киназы atr bay 1895344 для применения для лечения гиперпролиферативного заболевания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1209620 Country of ref document: HK |